- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04841447
Membrane Target Detection for Leukemia Treatment
Tumor Cell and DNA Detection in the Peripheral Blood of Patients With Hematological Malignancy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Specific targets and novel strategies to eliminate AML stem cells are required for AML treatment. Collecting specimens from the blood and bone marrow will increase understanding of the effect of DPP4 inhibitors on human AML-SCP to develop individualized therapies. We will test the effect of DPP4 inhibitors on human AML-SCP in vitro and in vivo and whether the addition of DPP4 inhibitors can prevent AML relapse once the disease is in the remission stage.
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. CML is a steadily developing blood and bone marrow disease that has three stages: chronic, accelerated, and blastic. If it reaches the blastic process, it is known as acute leukemia, which is the same as AML. While the mechanisms of BCR/ABL1-induced transformation are well understood, little is known about the effector molecules that contribute to leukemic SC (LSC) malignant expansion and extramedullary spread in CML. Furthermore, DPP4 is not only highly expressed in leukemia samples, but also specifically expressed in some of the other hematological malignancies, such as AML, CML, ALL, CLL, Lymphomas, or Myelomas, and may work as a stem cell marker as well. At this point, we would like to use human blood samples to investigate the role of DPP4 in hematological malignancy to deeply understand the role of DPP4 in leukemia.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Xunlei Kang, MD.PhD
- Phone Number: 5738844524
- Email: kangxu@health.missouri.edu
Study Contact Backup
- Name: Min Cao, MD
- Phone Number: 5738844524
- Email: caomi@health.missouri.edu
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- Recruiting
- University of Missouri
-
Contact:
- Xunlei Kang, MD.PhD
- Phone Number: 573-884-4524
- Email: kangxu@health.missouri.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All hematological malignancy patients.
- Must be 18 years old.
Exclusion Criteria:
- Participants with impaired decision-making capacities;
- Pregnant women or fetuses;
- Children (under 18 in Missouri, also dependent on State law);
- Non-viable neonates or neonates of uncertain viability (neonates=newborns);
- Non-English-speaking subjects;
- Prisoners.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DPP4 inhibitors measured in blood samples will be correlated with patient survival data.
Time Frame: 5 years
|
DPP4 inhibitors measured in blood samples will be used in vitro and in vivo a pre-clinical model.
|
5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018932
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancy
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Henry Ford Health SystemRecruitingHematological MalignancyUnited States
-
SanofiCompletedHematological MalignancyGreece, Spain, Peru, Israel, United States, Argentina, Belgium, Brazil, Chile, Finland, France, Italy, Mexico, Russian Federation, Turkey, Ukraine, United Kingdom
-
University of CopenhagenZealand University HospitalEnrolling by invitationHematological MalignancyDenmark
-
Washington University School of MedicineBarnes-Jewish HospitalTerminatedHematological MalignancyUnited States
-
Institut Paoli-CalmettesCompletedHematological MalignancyFrance
-
Peking University People's HospitalSanofiRecruitingHematological MalignancyChina
-
M.D. Anderson Cancer CenterNot yet recruiting
-
Beckman Coulter, Inc.Completed
-
Fate TherapeuticsTerminatedHematological MalignancyUnited States
Clinical Trials on Study sample collection
-
Chang Gung Memorial HospitalActive, not recruitingProsthetic Joint InfectionTaiwan
-
University of Missouri-ColumbiaRecruitingGastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Hepatocellular CancerUnited States
-
Boston Children's HospitalRecruitingGenetic Disease | Chopra-Amiel-Gordon Syndrome | CAGS | ANKRD17United States
-
Rothman Institute OrthopaedicsUnknownProsthetic Joint InfectionUnited States
-
Baylor College of MedicineCompletedCatheter-associated Bloodstream Infections (CLABSI)United States
-
Dana-Farber Cancer InstituteNational Institute of Nursing Research (NINR)CompletedAcute Myeloid Leukemia (AML)United States
-
Luxembourg Institute of HealthCentre Hospitalier du Luxembourg; Luxembourg Centre for Systems Biomedicine... and other collaboratorsRecruitingParkinson DiseaseLuxembourg
-
Wake Forest University Health SciencesInnoTech Precision MedicineNot yet recruitingOropharyngeal Squamous Cell Carcinoma | Human Papillomavirus InfectionUnited States
-
University Hospital, AngersRecruitingDevelopment Delay | Cancer Childhood | Predisposition, GeneticFrance, Réunion
-
Cambridge University Hospitals NHS Foundation TrustAstraZeneca; Cancer Research UK Cambridge InstituteRecruitingHigh-grade B-cell LymphomaUnited Kingdom